
Adding Sunharbo (asundexian), a first-in-class Factor XI inhibitor, to single or dual antiplatelet therapy reduces ischemic stroke risk without increasing the risk of major bleeding.
Year-end "Focus on": News and updates on the novel pharmacologic agents reviewed over the past 12 months; Focus on prasugrel; Pharmaceutical pipeline database products






